UPCOMING EVENTS & PRESENTATIONS
8:30 AM EDT
Please dial one of the following numbers 15 minutes prior to the start of the call:
United States: +1-866-966-1396
Access code: 5754875
The conference call will be broadcast live and will be available for replay for 30 days.
8:30 AM EST
An abstract discussing the study’s top-line results, ‘A Phase III Randomized, Double Blind, Placebo-Controlled, Multicenter, Parallel Group Study To Assess The Efficacy And Safety Of Add-On Fixed-Dose Anti-Mycobacterial Therapy (RHB-104) In Moderately To Severely Active Crohn's Disease (MAP US)’ was presented as a late-breaking abstract today at the United European Gastroenterology Week (UEG Week 2018) by Dr. David Y. Graham, M.D., Professor of Medicine, Molecular Virology and Microbiology at Baylor College of Medicine, Houston and Lead Investigator of the MAP US study.